JP2021502368A - 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用 - Google Patents

免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用 Download PDF

Info

Publication number
JP2021502368A
JP2021502368A JP2020525860A JP2020525860A JP2021502368A JP 2021502368 A JP2021502368 A JP 2021502368A JP 2020525860 A JP2020525860 A JP 2020525860A JP 2020525860 A JP2020525860 A JP 2020525860A JP 2021502368 A JP2021502368 A JP 2021502368A
Authority
JP
Japan
Prior art keywords
tumor
antibodies
cancer
tumors
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020525860A
Other languages
English (en)
Japanese (ja)
Inventor
ジェイミー ウェイチャート
ジェイミー ウェイチャート
ポール ソンデル
ポール ソンデル
ラヴィ パテル
ラヴィ パテル
ザカリー モーリス
ザカリー モーリス
ピーター カールソン
ピーター カールソン
レイニア ヘルナンデス
レイニア ヘルナンデス
ジョセフ グルジンスキ
ジョセフ グルジンスキ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/809,427 external-priority patent/US11633506B2/en
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of JP2021502368A publication Critical patent/JP2021502368A/ja
Priority to JP2023160419A priority Critical patent/JP2023179556A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0408—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N2005/1019—Sources therefor
    • A61N2005/1021—Radioactive fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020525860A 2017-11-10 2018-11-09 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用 Pending JP2021502368A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023160419A JP2023179556A (ja) 2017-11-10 2023-09-25 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/809,427 2017-11-10
US15/809,427 US11633506B2 (en) 2016-07-18 2017-11-10 Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
PCT/US2018/059927 WO2019094657A1 (en) 2017-11-10 2018-11-09 Using targeted radiotherapy (trt) to drive anti-tumor immune response to immunotherapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023160419A Division JP2023179556A (ja) 2017-11-10 2023-09-25 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用

Publications (1)

Publication Number Publication Date
JP2021502368A true JP2021502368A (ja) 2021-01-28

Family

ID=64665595

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020525860A Pending JP2021502368A (ja) 2017-11-10 2018-11-09 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用
JP2023160419A Pending JP2023179556A (ja) 2017-11-10 2023-09-25 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023160419A Pending JP2023179556A (ja) 2017-11-10 2023-09-25 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用

Country Status (7)

Country Link
EP (1) EP3706808A1 (enrdf_load_stackoverflow)
JP (2) JP2021502368A (enrdf_load_stackoverflow)
KR (1) KR102758660B1 (enrdf_load_stackoverflow)
CN (2) CN111565762A (enrdf_load_stackoverflow)
CA (1) CA3082056A1 (enrdf_load_stackoverflow)
IL (1) IL274518A (enrdf_load_stackoverflow)
WO (1) WO2019094657A1 (enrdf_load_stackoverflow)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3123873A1 (en) * 2018-12-21 2020-06-25 Actinium Pharmaceuticals, Inc. Combination radioimmunotherapy and immune checkpoint therapy in the treatment of cancer
MX2022006426A (es) * 2019-11-27 2022-06-22 Gi Innovation Inc Composicion farmaceutica para el tratamiento de cancer, que comprende inhibidor de punto de control inmunologico y proteina de fusion que incluye proteina il-2 y proteina cd80.
EP3842097A1 (en) * 2019-12-23 2021-06-30 Koninklijke Philips N.V. Planning radiation therapy using a personalized hematologic risk score
JP2023512214A (ja) 2020-01-28 2023-03-24 リフレクション メディカル， インコーポレイテッド 放射性核種および外部ビーム放射線療法の共同最適化
PE20221858A1 (es) * 2020-03-26 2022-11-30 Ramirez Fort Marigdalia Kaleth Tratamientos con radiacion ultravioleta
CN111840585B (zh) * 2020-07-20 2022-05-03 厦门大学 一种用于肿瘤免疫治疗的药物组合
US20220395702A1 (en) * 2021-06-10 2022-12-15 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for glioblastoma
KR20240142498A (ko) * 2022-01-28 2024-09-30 퓨전 파마슈티칼즈 인크. Ntsr1-표적화 방사성제약 및 체크포인트 억제제 조합 요법
WO2024258913A1 (en) * 2023-06-16 2024-12-19 Wisconsin Alumni Research Foundation Treatment of solid tumors with a regimen of targeted radionuclide therapy and genetically engineered immune cell therapies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528374A (ja) * 2004-03-02 2007-10-11 セレクター，リミティド ライアビリティ カンパニー Ｄｉａｐｅｕｔｉｃ（登録商標）剤としてのリン脂質類似体、及びその方法
JP2008545614A (ja) * 2004-12-20 2008-12-18 セレクター、リミテッド ライアビリティ カンパニー 癌の検出および治療のためのリン脂質エーテル類似体
JP2012530063A (ja) * 2009-06-12 2012-11-29 セレクター，インコーポレイティド 癌の治療並びに癌幹細胞の造影および検出のためのエーテルおよびアルキルリン脂質化合物
WO2016207732A1 (en) * 2015-06-25 2016-12-29 Advanced Accelerator Applications Method of treatment of neuroendocrine tumors that over-express somatostatatin receptors
WO2017079535A1 (en) * 2015-11-06 2017-05-11 Wisconsin Alumni Research Foundation Long-lived gadolinium based tumor targeted imaging and therapy agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
EP3334465A1 (en) * 2015-08-12 2018-06-20 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer
US11633506B2 (en) * 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
AU2017300361B2 (en) * 2016-07-18 2024-08-01 Wisconsin Alumni Research Foundation Radiohalogenated agents for In Situ Immune Modulated Cancer Vaccination
US20180022768A1 (en) 2016-07-25 2018-01-25 Wisconsin Alumni Research Foundation Radioactive phospholipid metal chelates for cancer imaging and therapy
EP3487530B1 (en) * 2016-07-25 2024-03-20 Wisconsin Alumni Research Foundation Targeted radiotherapy chelates for in situ immune modulated cancer vaccination

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528374A (ja) * 2004-03-02 2007-10-11 セレクター，リミティド ライアビリティ カンパニー Ｄｉａｐｅｕｔｉｃ（登録商標）剤としてのリン脂質類似体、及びその方法
JP2008545614A (ja) * 2004-12-20 2008-12-18 セレクター、リミテッド ライアビリティ カンパニー 癌の検出および治療のためのリン脂質エーテル類似体
JP2012530063A (ja) * 2009-06-12 2012-11-29 セレクター，インコーポレイティド 癌の治療並びに癌幹細胞の造影および検出のためのエーテルおよびアルキルリン脂質化合物
WO2016207732A1 (en) * 2015-06-25 2016-12-29 Advanced Accelerator Applications Method of treatment of neuroendocrine tumors that over-express somatostatatin receptors
WO2017079535A1 (en) * 2015-11-06 2017-05-11 Wisconsin Alumni Research Foundation Long-lived gadolinium based tumor targeted imaging and therapy agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LAWRENCE FONG: "ABSTRACT CT031: A PHASE IB TRIAL TO STUDY THE SAFETY AND TOLERABILITY OF ATEZOLIZUMAB 以下備考", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. VOL:77, NR:13, JPN5021003370, July 2017 (2017-07-01), ISSN: 0005209378 *
MAARTEN SWART; ET AL: "COMBINATION APPROACHES WITH IMMUNE-CHECKPOINT BLOCKADE IN CANCER THERAPY", FRONTIERS IN ONCOLOGY, vol. 6, JPN5021003372, November 2016 (2016-11-01), XP055558918, ISSN: 0005209380, DOI: 10.3389/fonc.2016.00233 *
STORKUS W.: "Combination treatment of VLA-4 targeted radionuclide therapy and immunotherapy for metastatic melano", MOLECULAR IMAGING AND BIOLOGY, vol. Vol.19, No.1 Suppl., JPN6022033005, September 2017 (2017-09-01), pages 419, ISSN: 0005209377 *
WEICHERT J P; ET AL: "ALKYLPHOSPHOCHOLINE ANALOGS FOR BROAD-SPECTRUM CANCER IMAGING AND THERAPY", SCIENCE TRANSLATIONAL MEDICINE, vol. VOL:6, NR:240,, JPN5021003371, 11 June 2014 (2014-06-11), US, pages 240 - 75, ISSN: 0005209379 *

Also Published As

Publication number Publication date
CN120550150A (zh) 2025-08-29
CA3082056A1 (en) 2019-05-16
JP2023179556A (ja) 2023-12-19
AU2018366219A1 (en) 2020-06-11
IL274518A (en) 2020-06-30
KR102758660B1 (ko) 2025-01-22
CN111565762A (zh) 2020-08-21
WO2019094657A1 (en) 2019-05-16
KR20200088374A (ko) 2020-07-22
EP3706808A1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
US20230398239A1 (en) Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
KR102758660B1 (ko) 면역요법에 대한 항-종양 면역 반응을 유도하기 위해 표적화된 방사선요법(trt)을 이용하는 방법
US11730834B2 (en) Targeted radiotherapy chelates for in situ immune modulated cancer vaccination
US12109256B2 (en) Radiohalogenated agents for in situ immune modulated cancer vaccination
AU2018366219B2 (en) Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
TW202332473A (zh) 放射性核種複合物的組合療法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230925

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231113

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231208